Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
40 results about "Heart transplantation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A heart transplant, or a cardiac transplant, is a surgical transplant procedure performed on patients with end-stage heart failure or severe coronary artery disease when other medical or surgical treatments have failed. As of 2018, the most common procedure is to take a functioning heart, with or without transplanting one or both lungs at the same time, from a recently deceased organ donor (brain death is the standard) and implanting it into the patient. The patient's own heart is either removed and replaced with the donor heart (orthotopic procedure) or, much less commonly, the recipient's diseased heart is left in place to support the donor heart (heterotopic, or "piggyback", transplant procedure).
Chronic Rejection Inhibitor
ActiveUS20100061986A1Suppressing chronic rejection reactionAvoid spreadingAntibody ingredientsImmunoglobulinsHeart transplantationStenotic lesion
The present inventors assessed the effect of anti-IL-6 receptor antibodies in suppressing chronic rejection reaction. They assessed the effect of anti-mouse IL-6 receptor antibody (MR16-1) administration in suppressing the chronic rejection reaction using a mouse model for post-heart-transplantation chronic rejection. The result of histopathological analysis of transplanted hearts extirpated 60 days after transplantation revealed that fibrosis of myocardium and vascular stenotic lesions, which are pathological conditions characteristic of the chronic rejection reaction, were significantly suppressed in the MR16-1-treated group as compared to the control group. Thus, MR16-1 administration was demonstrated to have the effect of suppressing chronic rejection reaction. Specifically, the present inventors discovered for the first time that the rejection reaction in the chronic phase after organ transplantation was suppressed by administering an anti-IL-6 receptor antibody.
Owner:CHUGAI PHARMA CO LTD +1
Method of inotropic treatment of circulatory failure using hypothermia
InactiveUS7172586B1Control rateIncrease contractilityStentsSurgeryHeart transplantationAutomatic control
A method for treating cardiac failure such as congestive heart failure by application of hypothermia. Hypothermia may be applied by endovascular cooling using a heat exchange catheter circulating heat exchange fluid between an external heat exchanger controlled using temperature feedback from a temperature probe on or in the patient to cool the heart to a sufficiently low temperature for a sufficient length of time to increase cardiac output and improve the vascular condition of the patient. The patient may be maintained in the hypothermic condition for a period of time and is then re-warmed slowly and controllably. The endovascular temperature management may be controlled automatically in response to a temperature probe on the patient, and shivering while the patient is cool may be combated using surface warming and anti-shivering drugs. The method is applicable to treat congestive heart failure and may be used repeatedly on the same patient to restore that patient to adequate heart function when the vascular condition of that patient has become unacceptable. The method may be used to maintain a patient until a heart transplant becomes available. The method may be used to stabilize a patient's condition to allow needed surgery or intervention. The method may be used in conjunction with other treatments including drugs, balloon pumps, pacing devices and ventricular assist devices.
Owner:ZOLL CIRCULATION
Cellular cardiomyoplasty as supportive therapy in patients with heart disease
ActiveUS20060276685A1Improve the quality of lifeImprove heart functionMammal material medical ingredientsSkeletal/connective tissue cellsDiseaseHeart transplantation
The present invention provides a system for treating heart disease as a “bridge to recovery” using cellular cardiomyoplasty. The system is particularly useful in selecting and treating patients with damaged myocardium due coronary artery disease, myocardial infarction, congestive heart failure, and ischemia. Based on various clinical criteria, a patient is selected and optionally treated using cellular cardiomyoplasty to improve the patient's cardiac function. The cardiomyoplasty may be combined with other treatments such as medications or left ventricular assist devices. Preferably, the cellular cardiomyoplasty eliminates the need for invasive surgery such as by-pass grafting or cardiac transplantation. The invention also provides kits for use in selecting and treating patients using the inventive method.
Owner:MYTOGEN
(2E)-3-phenyl-N-[2,2,2-trichlorine-1-[[(8-quinolyl amino) thiomethyl]amino]ethyl]-2-acrylamide and medicinal uses thereof
ActiveCN102241628AReduce lesionsUses to improve hardeningOrganic active ingredientsOrganic chemistryDiseaseHeart transplantation
The invention relates to an acrylamide compound with a structural formula I or an isomer thereof, a pharmaceutical salt thereof and a solvate thereof, and also relates to the compound or the isomer thereof or the pharmaceutical salt thereof and the solvate thereof, a composition of a pharmaceutically acceptable vector, an excipient or a diluent, and uses of the compound or the composition in preventing and / or treating diseases or symptoms which relate to cardiomyocyte apoptosis and include but are not limited to the uses of (i) treating hungry myocardial atrophy, (ii) treating myocarditis, (iii) treating cardiac failure, (iv) treating or relieving myocardial damage caused by essential hypertension, (v) treating or relieving myocardial damage caused by early-stage acute myocardial infarction, (vi) treating or relieving myocardial damage caused by acute myocardial infarction reperfusion, (vii) treating or relieving cardiomyocyte pathology caused by heart transplant, (viii) treating or relieving dysplastic cardiomyopathy, cardiomyocyte apoptosis caused by anoxia, or improving cardiovascular system sclerosis.
![(2E)-3-phenyl-N-[2,2,2-trichlorine-1-[[(8-quinolyl amino) thiomethyl]amino]ethyl]-2-acrylamide and medicinal uses thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/0a1ec01a-74be-4f12-a146-ea7a106464e2/HSA00000105871800011.png "(2E)-3-phenyl-N-[2,2,2-trichlorine-1-[[(8-quinolyl amino) thiomethyl]amino]ethyl]-2-acrylamide and medicinal uses thereof")
![(2E)-3-phenyl-N-[2,2,2-trichlorine-1-[[(8-quinolyl amino) thiomethyl]amino]ethyl]-2-acrylamide and medicinal uses thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/0a1ec01a-74be-4f12-a146-ea7a106464e2/HSA00000105871800012.png "(2E)-3-phenyl-N-[2,2,2-trichlorine-1-[[(8-quinolyl amino) thiomethyl]amino]ethyl]-2-acrylamide and medicinal uses thereof")
![(2E)-3-phenyl-N-[2,2,2-trichlorine-1-[[(8-quinolyl amino) thiomethyl]amino]ethyl]-2-acrylamide and medicinal uses thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/0a1ec01a-74be-4f12-a146-ea7a106464e2/FSA00000105871600011.png "(2E)-3-phenyl-N-[2,2,2-trichlorine-1-[[(8-quinolyl amino) thiomethyl]amino]ethyl]-2-acrylamide and medicinal uses thereof")
Owner:GENERAL HOSPITAL OF PLA
Carboxylic acid derivatives and drugs containing the same as the active ingredient
Compounds represented by formula (I), prodrugs thereof and salts thereof, and pharmaceutical compositions comprising the same as an active ingredient (wherein each symbol has the meaning as defined in the specification.).Because of having an EDG-1 agonism, the compounds represented by formula (I) are useful in preventing and / or treating peripheral arterial disease such as arteriosclerosis obliterans, thromboangiitis obliterans, Buerger's disease or diabetic neuropathy, sepsis, angiitis, nephritis, pneumonia, stroke, myocardial infarction, edematous state, atherosclerosis, varicosity such as hemorrhoid, anal fissure or fistula ani, dissecting aneurysm of the aorta, angina, DIC, pleuritis, congestive heart failure, multiple organ failure, bedsore, burn, chronic ulcerative colitis, Crohn's disease, heart transplantation, renal transplantation, dermal graft, liver transplantation, osteoporosis, pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, liver cirrhosis, chronic renal failure, or glomerular sclerosis.
Owner:ONO PHARMA CO LTD
Method of using amnion allograft in heart transplant surgery
InactiveUS20130209524A1Suitable shapeReduce sizeBiocidePharmaceutical delivery mechanismHeart transplantationImproved method
Owner:LIVENTA BIOSCI
Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient
Compounds represented by formula (I), prodrugs thereof and salts thereof, and pharmaceutical compositions comprising the same as an active ingredient (wherein each symbol has the meaning as defined in the specification.). Because of having an EDG-1 agonism, the compounds represented by formula (I) are useful in preventing and / or treating peripheral arterial disease such as arteriosclerosis obliterans, thromboangiitis obliterans, Buerger's disease or diabetic neuropathy, sepsis, angiitis, nephritis, pneumonia, stroke, myocardial infarction, edematous state, atherosclerosis, varicosity such as hemorrhoid, anal fissure or fistula ani, dissecting aneurysm of the aorta, angina, DIC, pleuritis, congestive heart failure, multiple organ failure, bedsore, burn, chronic ulcerative colitis, Crohn's disease, heart transplantation, renal transplantation, dermal graft, liver transplantation, osteoporosis, pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, liver cirrhosis, chronic renal failure, or glomerular sclerosis.
Owner:ONO PHARMA CO LTD
Application of ring icariine in the preparation of medicine for preventing and treating organ transplantation rejection
InactiveCN1919191ASuppression of rejectionFunction increaseSolution deliveryPill deliveryHeart transplantationMedicine
The invention discloses an immune inhibiting drug and application based on ring-icariin in the formula I, which is characterized by the following: inhibiting immuse exclusive reaction in the organ transplanting course, modifying transplanted organ function.
Owner:SUN YAT SEN UNIV
Application of nitidine chloride to preparation of medicament for resisting autoimmunity disease and graft versus host disease
InactiveCN102008474ARich sourcesLow cost of treatmentOrganic active ingredientsSenses disorderInterleukin 10Dendritic cell
The invention provides application of nitidine chloride to the preparation of a medicament for resisting autoimmunity disease and graft versus host disease. An experiment shows that the nitidine chloride can inhibit the proliferation of human dendritic cells in vitro, inhibit the human dendritic cells from promoting the proliferation reaction of allogeneic T cells and strengthen the capacity of secreting interleukin 10 of the human dendritic cells. Meanwhile, in an experimental autoimmunity disease cerebrospinal meningitis model, when used in vivo, the nitidine chloride can reduce the average clinical score of a mouse and inhibit the spinal marrow infiltration degree of monocytes and can obviously improve the secretion level of the interleukin 10 in the blood serum of the mouse. In a heart transplantation experiment, when used in vivo, the nitidine chloride can prolong the survival time of the transplanted heart. In a delayed type hypersensitivity reaction model, when used in vivo, the nitidine chloride can reduce the ear swelling degree of the mouse. Both in-vivo and in-vitro results show that the nitidine chloride has a certain effect of resisting the autoimmunity disease and the graft versus host disease. The medicament is a preparation which consists of the nitidine chloride serving as an active ingredient and a pharmaceutical carrier. The medicament can be prepared into an oral preparation, an injection, a suppository or an external preparation and the like.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Hemodynamic Assist Device
A hemodynamic flow assist device includes a miniature pump, a basket-like cage enclosing and supporting the pump, and a motor to drive the pump. The device is implanted and retrieved in a minimally invasive manner via percutaneous access to a patient's artery. The device has a first, collapsed configuration to assist in implantation and a second, expanded configuration once deployed and active. The device is deployed within a patient's aorta and is secured in place via a self-expanding cage which engages the inner wall of the aorta. The device includes a helical screw pump with self-expanding blades, sensors, and anchoring structures. Also disclosed is a retrieval device to remove the hemodynamic flow assist device once it is no longer needed by the patient and an arterial closure device to close the artery access point after implantation and removal of the hemodynamic flow assist device. The hemodynamic flow assist device helps to increase blood flow in patients suffering from congestive heart failure and awaiting heart transplant.
Owner:HRIDAYA
Heart assistant device
PendingCN110478546AAuxiliary jumpSurgical needlesControl devicesHeart transplantationCardiac failures
The invention discloses a heart assistant device. The heart assistant device comprises a catheter and a plurality of supporting blades; each supporting blade comprises a shell and a flexible bag, wherein each flexible bag is connected with a medium pumping out-in device through a connecting tube, and arranged on the corresponding shell, and after a medium is pumped into the flexible bags, the flexible bags can swell, and at least parts of the flexible bags can be exposed outside the corresponding shells; the heart assistant device also comprises a guide mechanism and a push mechanism, whereinthe guide mechanism is used for guiding the catheter in being inserted into the pericardium, the push mechanism can drive the supporting blades to perform displacement along the catheter and stretch out of the catheter, the shells are made from memory alloy, and in the stretched state, the supporting blades can be unfolded to coat the heart or the specific ventricle. The provided heart assistant device can assist the heart or the specific ventricle in beating, thereby performing auxiliary treatment on a patient with cardiac failure to buy time for a heart transplantation operation.
Owner:BEIJING ANZHEN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
Methods and Solutions for Tissue Preservation
InactiveUS20080286745A1Promote resultsReduce ischemic, hypothermic and reperfusion injuringDead animal preservationHeart transplantationReperfusion injury
Described herein are compositions and methods particularly useful in the medical arts. The compositions and methods may be used in connection with the preservation of a portion of a mammal, for example, tissues, organs, appendages, limbs, extremities, stem cells, myocytes, bone marrow, skeletal muscle as well as an array of other medical procedures, such as cardiac surgery, transplantation and / or preservation. In various embodiments, the inventive composition may be hyperoxygenated and be formulated to resemble the biochemistries of natural intracellular fluids. The inventive composition includes active ingredients to reduce ischemic, hypothermic and reperfusion injury during transplantation, thereby resulting in improved post-transplant graft function and quality, when used in connection with organ transplantation and storage procedures, for example cardiac transplantation.
Owner:CEDARS SINAI MEDICAL CENT
Application of lariciresinol to preparing medicament for resisting autoimmune disease and graft rejection disease
InactiveCN101991566AInhibitionInhibition of developmentOrganic active ingredientsSenses disorderInterleukin 10White blood cell
The invention provides application of lariciresinol to preparing a medicament for resisting an autoimmune disease and a graft rejection disease. An experiment discovers that: the lariciresinol can inhibit human dendritic cell proliferation in vitro and inhibit the capability of human dendritic cells of promoting allogeneic T cell proliferation reaction and enhancing the secretion of interleukin 10. Meanwhile, in an experimental autoimmune myelomeningitis model, the lariciresinol is applied in vivo, so that an average clinical score of mice can be reduced and the spinal infiltration of mononuclear cells is inhibited. In a heart transplant experiment, the lariciresinol is applied in vivo, so that the survival time of a transplanted heart is prolonged. In a delayed hypersensitivity model, the lariciresinol is applied in vivo, so that the auricle swelling degree of the mice can be reduced. In-vivo and in-vitro results both show that: the lariciresinol has the certain effect of resisting the autoimmune disease and graft rejection disease. The medicament is a preparation which consists of the lariciresinol serving as an active ingredient and a medical carrier, and comprises an oral preparation, an injection, a suppository, an external preparation and the like.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Chimeric combined vascular anastomosis device
InactiveCN104905836AEasy to manufactureImprove the level ofSurgical staplesPostoperative complicationVascular anastomosis
The invention discloses a chimeric combined vascular anastomosis device. The chimeric combined vascular anastomosis device comprises two parts, namely, an acceptor end and a donor end, the acceptor end and the donor end are of annular structures, the sizes of the acceptor end and the donor end are matched with blood vessels of the acceptor end and blood vessels of the donor end respectively, a chimeric mechanism is arranged on the acceptor end and the donor end, and close gomphosis of the acceptor end and the donor end can be achieved through the chimeric mechanism. The vascular anastomosis device is suitable for vascular anastomosis in the operative processes of organ transplantation such as liver transplantation and heart transplantation. In the operative processes of the organ transplantation, fast, accurate and reliable vascular anastomosis can be achieved, operative process is greatly simplified, the operative difficulty and labor strength of operators are lowered, no organ period and intraoperative blood vessel blocking time are shortened, the operative success rate is improved, and the postoperative complication is lowered.
Owner:臧运金
Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
InactiveUS20050054618A1Easy to useIncrease successBiocidePeptide/protein ingredientsHeart transplantationCoronary artery disease
The present invention provides methods of treatment and prevention of early cardiac and early cardiovascular diseases, for instance of ischemic origin, such as left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, arteriosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, intermittent claudication (arteriosclerosis oblitterens), diastolic dysfunction and systolic dysfunction, as well as improving the success of heart transplantations, through administration of glycogen phosphorylase inhibitor compounds.
Owner:RYTVED KLAUS ASGER +4
Cellular cardiomyoplasty as supportive therapy in patients with heart disease
ActiveUS8889122B2Improve the quality of lifeImprove heart functionBiocideMammal material medical ingredientsHeart transplantationCoronary artery disease
The present invention provides a system for treating heart disease as a “bridge to recovery” using cellular cardiomyoplasty. The system is particularly useful in selecting and treating patients with damaged myocardium due coronary artery disease, myocardial infarction, congestive heart failure, and ischemia. Based on various clinical criteria, a patient is selected and optionally treated using cellular cardiomyoplasty to improve the patient's cardiac function. The cardiomyoplasty may be combined with other treatments such as medications or left ventricular assist devices. Preferably, the cellular cardiomyoplasty eliminates the need for invasive surgery such as by-pass grafting or cardiac transplantation. The invention also provides kits for use in selecting and treating patients using the inventive method.
Owner:MYTOGEN
Intractable heart failure left ventricular function auxiliary device
PendingCN110124133AReduce mortalityElectrocardiographyMedical devicesHeart transplantationLeft ventricular size
The invention discloses an intractable heart failure left ventricular function auxiliary device. Various straws and cavity tunnels are designed in a suction head, outer sucking holes are formed in thelower wall and the outer side of the suction head, a straw is led to a proximal end conical cavity inwards, a one-way valve is designed at a position communicated with the cavity in a pipeline of thestraw, the straw is communicated with an inner cavity of an air bag through the one-way valve, a single channel is connected with the drop-shaped suction head in a straw valve crossing section, a distal end is communicated with an air bag chamber, four one-way valves are arranged on the outer wall of the trapezoid side surface of a capsule and communicated with an inner cavity of the air bag chamber through channels, conical upper end is connected with an air-space tunnel through a trachea, branch tracheae pass the air bag chamber downwards and are opened on the inner side of the wall of theair bag and converged into a main trachea upwards, the main trachea is communicated with outside thought an artery, and the lower end of a guide wire is communicated with the drop-shaped suction head.The device has the advantages that the device can continuously work under the condition of left ventricular function loss, and time is bought for clinical rescue or heart transplantation.
Owner:THE AFFILIATED HOSPITAL OF QINGDAO UNIV
Minimally invasive catheter type synchronous cardiac auxiliary device and use method thereof
PendingCN108310497ALow costCompact structureElectrocardiographyMedical devicesHeart transplantationLeft ventricular size
The invention relates to the field of cardiac auxiliary circulation, in particular to a minimally invasive catheter type synchronous cardiac auxiliary device and a use method thereof. An execution portion comprises an inner cavity, the inner cavity is enclosed by a cavity wall to form an entirety with a cylindrical shape, and the formed inner cavity enclosed by the cavity wall is used for placingan intermediate gasbag; the front and back ends of the inner cavity are respectively provided with a front end gasbag and a back end gasbag which have valve effects, the front gasbag, the back end gasbag and the intermediate gasbag are respectively and externally connected with an air bump through flexible tubes, and an execution piece is controlled by a control module and is matched with a patient cardiac impluse characteristic to boost blood in the left ventricular to the aorta. According to the minimally invasive catheter type synchronous cardiac auxiliary device, it can be achieved that the blood in the left ventricular can be boosted to the aorta, significant effects are performed on patient recovery after cardiovascular surgery, heart transplantation transition or replacement, myocardial function recovery and permanent treatment of cardiac failure, the cost is low, the device structure is simple and compact, and it is convenient to popularize and promote the device.
Owner:ANHUI TONGLING BIONIC TECH CO LTD
Method for screening optimal gene combination of heterograft donor pig
InactiveCN108342491AShorten screening timeReduce blindnessMicrobiological testing/measurementHeart transplantationAnimal biotechnology
The invention relates to a method for screening an optimal gene combination of a heterograft donor pig and belongs to the technical field of animal biologics. By taking human fibroblast as a study target, an in-vitro compatibility evaluation method for human fibroblast is established, results of reported pig fibroblast modified with heart or other genes with long transplantation survival times canbe verified by using the method, and relatively applicable complement adjustment factors, immune response factors and anticoagulation factors can be screened; on the basis of GTKO (Gene Transferase Knockout), the factors are combined and are subjected to fixed knock-in or knockout, pig fibroblast of different multi-factor combinations is subjected to early-stage screening, then cells of more thanthree optimal gene combinations are recloned, cloned pigs are subjected to heart transplantation of pig-non-primate animals, and the reliability of the screening method can be verified. By adopting the method, an optimal gene combination can be evaluated without the basis that a gene combination modified pig is available, so that the gene combination screening time and the investment cost can begreatly reduced, and the method has great significances in development of real heterograft donor pigs.
Owner:YUNNAN AGRICULTURAL UNIVERSITY
Application of blood serum sST2 in dilated cardiomyopathy prognosis
ActiveCN108982871AImprove predictive performanceIncreased sensitivityDisease diagnosisBiological testingDiseaseHeart transplantation
The invention provides a novel use of a substance for detecting content of soluble ST2 (sST2) protein and a novel use of taking the soluble ST2 (sST2) as a blood serum marker. The sST2 which is takenas the blood serum marker can be independently applied to risk stratification of a child patient with dilated cardiomyopathy (DCM) and predication of an adverse event (all-cause mortality / heart transplantation / rehospitalization as a result of congestive heart failure); meanwhile, the sST2 which is taken as the blood serum marker can improve predication ability of a conventional marker-BNP, can be used for monitoring DCM child patient disease progression and is not affected by a renal function and BMI. The application provides scientific basis for monitoring risk stratification, prognosis anddisease progression of the patient with dilated cardiomyopathy, greatly and positively intervenes a decision opportunity clinically before the adverse event occurs, makes up the research and clinicalapplication blank of the medical industry, and has great potential and value of clinical and market application.
Owner:BEIJING INST OF HEART LUNG & BLOOD VESSEL DISEASES
Application of quercetin in preparing medicaments for treating organ transplant rejection reactions
InactiveCN101966195ASignificantly against immune rejectionLow toxicityOrganic active ingredientsImmunological disordersHeart transplantationOrgan transplantation
The invention discloses the application of quercetin in preparing medicaments for treating organ transplant rejection reactions. The quercetin can be used for treating rejection reactions generated by inhibited tissue organs, such as liver, kidney, bone marrow, cornea, skin and heart transplantation. The invention also relates to the preparation of quercetin compositions.
Owner:张景元
Heart auxiliary stent balloon system, production method thereof and heart assisting device
PendingCN110559497AReduce the risk of blood clotsShort strokeMedical devicesIntravenous devicesHeart transplantationLife quality
The invention discloses a heart auxiliary stent balloon, which belongs to the field of organ auxiliary devices. The heart auxiliary stent balloon comprises a stent made of a memory metal and a capsulefilm made of an elastic material, the capsule film is sleeved at one end of the stent to form an air bag; an air duct communicated with the interior of the air bag is arranged in the stent; wherein aplurality of groups of access channels are arranged in the stent, and each group of access channels consists of a channel entry section and a channel exit section which are arranged side by side andhave one communicated ends; and the end parts of the ends, communicated with each other, of the channel entry section and the channel exit section in each group of access channels extend into different positions of the stent. The heart auxiliary stent balloon is implanted through percutaneous puncture, is easy to disassemble and assemble, simulates a physiological working state of the heart to a maximum extent, plays a role in heart assistance, is beneficial to recovery of the physiological function of damaged myocardium and improvement of the living quality of a patient, and can be used in atransition period before heart transplantation. The method is simple, cost is saved for the patient, and safety of the patient is guaranteed.
Owner:THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIV
Application of Incarvillea delavay alkali in preparing drug for resisting autoimmune diseases and graft rejection diseases
InactiveCN102008468BRich sourcesLow cost of treatmentOrganic active ingredientsSenses disorderHeart transplantationAutoimmune condition
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Novel method for treating chronic severe heart failure by using insulin-like growth factor-1 (igf-1)
InactiveUS20090012499A1Improve cardiovascular functionSymptoms improvedPeptide/protein ingredientsMedical devicesDiseaseHeart transplantation
The present invention relates to novel method for treating chronic severe heart failure by using insulin-like growth factor-1 (IGF-1). More specifically, the present invention relates to method for improving cardiovascular function and symptoms in a patient with chronic severe heart failure by administering IGF-1 to the patient for a certain period, wherein no options for treating the disorder the patient remain other than heart transplantation.
Owner:NAT INST FOR MATERIALS SCI +1
Anti-cav peptide analogue and corresponding cdna and its application
ActiveCN105601733BEnhanced interactionEfficient expressionPeptide/protein ingredientsProtease inhibitorsHeart transplantationComplementary deoxyribonucleic acid
The invention discloses a polypeptide analog for resisting heart implant vasculopathy, and a corresponding cDNA (complementary deoxyribonucleic acid) and application thereof. On the basis of the establishment of the TIMP-1 and MMP-14 interaction structure field in CAV, the invention provides a method for producing a recombinant polypeptide analog myc HisA-TIMP-1[triangle102-217aa] by a gene engineering process. The polypeptide analog has the advantages of high expression efficiency and simple purification technique, and is beneficial to further large-scale preparation. The polypeptide analog can promote the interaction between TIMP-1 and MMP-14, inhibit the VSMC transfer after heart transplantation and inhibit the CAV from generation and development. The polypeptide analog can provide theoretical references for searching for effective intervention target spots for CAV and developing new therapeutic drugs. The polypeptide analog has very important development prospects for implementing long-term survival of heartmen after CAV clinical therapy.
Owner:NANTONG TENGZHONG MACHINERY
Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
InactiveUS6960610B2Easy to useIncrease successBiocideAnimal repellantsHeart transplantationCoronary artery disease
The present invention provides methods which may effectively be used in the treatment and prevention of early cardiac and early cardiovascular diseases, for example of ischemic origin, such as left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, arteriosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, intermittent claudication (arteriosclerosis oblitterens), diastolic dysfunction and systolic dysfunction, as well as improving the success of heart transplantations, through administration of glycogen phosphorylase inhibitor compounds.
Owner:NOVO NORDISK AS
Application of JQ1 in preparing organ transplantation immunological rejection inhibiting medicines
ActiveCN108096252AConducive to survivalLower immune responseOrganic active ingredientsImmunological disordersBALB/cHeart transplantation
The invention provides an application of JQ1 in preparing organ transplantation immunological rejection inhibiting medicines, in particular an application in preparing medicines for preventing and treating cardiac transplantation immunological rejection. Based upon experiments, it is proved that the survival time of transplanted hearts of an allogeneic mice (C57BL / 6 to BALB / c) in a control group is 7-10 days, while the survival time of transplanted hearts of mice applied with the JQ1 can reach 25 days to the greatest extent, indicating that the JQ1 provided by the invention is beneficial for reducing an alloimmunity reaction and prolonging the survival of transplants. The JQ1, as a novel small-molecule inhibitor, can solve the problem that transplanted organs are low in survival rate for along time due to rejection, and the JQ1 can offer a basis for preparing organ transplantation immunological rejection inhibiting preparations; therefore, an effective approach is provided for treating such chronic end-stage diseases such as liver diseases, renal diseases, cardiac diseases and the like.
Owner:ZHEJIANG UNIV
A miRNA-182 inhibitor and its application in the preparation of drugs for preventing and treating immune rejection in heart transplantation
ActiveCN105748501BLower immune responseConducive to survivalOrganic active ingredientsGenetic material ingredientsHeart transplantationCholesterol
Owner:成都仕康美生物科技有限公司
Application of p-hydroxyl acetophenone glycosidase to medicine for autoimmunity disease and transplant rejection disease
InactiveCN103316025BRich sourcesInhibitionOrganic active ingredientsNervous disorderDiseaseDendritic cell
The present invention provides application of p-hydroxyl acetophenone glycosidase to medicine for autoimmunity disease and transplant rejection disease. Through experiments, p-hydroxyl acetophenone glycosidase is found to be capable of restraining multiplication of human dendritic cells in vitro, restraining human denderitic cells to promote breeder reaction of allogeneic T cells, and enhancing the ability of human denderitic cells to secrete interleukin 10. In a model of experimental autoimmunity disease cerebrospinal meningitis, p-hydroxyl acetophenone glycosidase is capable of reducing an average mouse clinical score and restraining spinal cord invasion degree of the mononuclear cells. In an experiment of heart transplantation, p-hydroxyl acetophenone glycosidase is capable of prolonging the survival time of the transplanted heart. In a model of delayed type hypersensitivity, p-hydroxyl acetophenone glycosidase is capable of reducing mouse ear swelling degree. According to the results both in vivo and in vitro, p-hydroxyl acetophenone glycosidase possesses a certain effect on autoimmunity disease and transplant rejection disease. The medicine provided by the invention comprises p-hydroxyl acetophenone glycosidase as an active component and a medicinal carrier, and the medicine includes oral dosage form, injection, suppository, and topical dosage form, etc.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Anti-CAV polypeptide analog, and corresponding cDNA (complementary deoxyribonucleic acid) and application thereof
ActiveCN105601733AEnhanced interactionEfficient expressionPeptide/protein ingredientsProtease inhibitorsHeart transplantationComplementary deoxyribonucleic acid
Owner:NANTONG TENGZHONG MACHINERY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com